Early detection and mitigation of disease recurrence in non-small cell lung cancer (NSCLC) patients is a nontrivial problem that is typically addressed either by rather generic follow-up screening guidelines, self-reporting, simple nomograms, or by models that predict relapse risk in individual patients using statistical analysis of retrospective data. We posit that machine learning models trained on patient data can provide an alternative approach that allows for more efficient development of many complementary models at once, superior accuracy, less dependency on the data collection protocols and increased support for explainability of the predictions. In this preliminary study, we describe an experimental suite of various machine learnin...
Purpose: Tumors are continuously evolving biological systems, and medical imaging is uniquely positi...
INTRODUCTION Between 10 and 50% of early-stage lung adenocarcinoma patients experience local or d...
International audienceBackground: Immune checkpoint inhibitors (ICIs) are now a therapeutic standard...
BackgroundSurveillance is universally recommended for non-small cell lung cancer (NSCLC) patients tr...
Purpose: Non-small-cell lung cancer (NSCLC) shows a high incidence of brain metastases (BM). Early d...
Introduction: Evaluation of treatment response is one of the most challenging tasks in the treatment...
Some early stage NSCLC patients have a better survival prospects than others. In any event, the long...
Copyright © 2022 The Authors. Machine learning is an important artificial intelligence technique tha...
Background: Prognostic risk factors for completely resected stage IA non-small-cell lung cancers (NS...
Due to high recurrence rates in patients with non-small cell lung cancer (NSCLC), medical profession...
Background. After curative surgical resection, about 30-75% lung adenocarcinoma (LUAD) patients suff...
The early symptoms of lung cancer, a serious threat to human health, are comparable to those of the ...
Lung cancer has the highest mortality rate among all cancer types in the United States, comprising a...
Lung cancer is the leading cause of cancer-related death around the world. Early detection is a crit...
Purpose The aim of the present study was to investigate the predictive ability for lung cancer of sy...
Purpose: Tumors are continuously evolving biological systems, and medical imaging is uniquely positi...
INTRODUCTION Between 10 and 50% of early-stage lung adenocarcinoma patients experience local or d...
International audienceBackground: Immune checkpoint inhibitors (ICIs) are now a therapeutic standard...
BackgroundSurveillance is universally recommended for non-small cell lung cancer (NSCLC) patients tr...
Purpose: Non-small-cell lung cancer (NSCLC) shows a high incidence of brain metastases (BM). Early d...
Introduction: Evaluation of treatment response is one of the most challenging tasks in the treatment...
Some early stage NSCLC patients have a better survival prospects than others. In any event, the long...
Copyright © 2022 The Authors. Machine learning is an important artificial intelligence technique tha...
Background: Prognostic risk factors for completely resected stage IA non-small-cell lung cancers (NS...
Due to high recurrence rates in patients with non-small cell lung cancer (NSCLC), medical profession...
Background. After curative surgical resection, about 30-75% lung adenocarcinoma (LUAD) patients suff...
The early symptoms of lung cancer, a serious threat to human health, are comparable to those of the ...
Lung cancer has the highest mortality rate among all cancer types in the United States, comprising a...
Lung cancer is the leading cause of cancer-related death around the world. Early detection is a crit...
Purpose The aim of the present study was to investigate the predictive ability for lung cancer of sy...
Purpose: Tumors are continuously evolving biological systems, and medical imaging is uniquely positi...
INTRODUCTION Between 10 and 50% of early-stage lung adenocarcinoma patients experience local or d...
International audienceBackground: Immune checkpoint inhibitors (ICIs) are now a therapeutic standard...